Trial NCT04739410
Publication Khan Chachar AZ, Int J Sci, 2020 (published paper)

Funding: No specific funding
Conflict of interest: *

Methods
RCT
Blinding: Unblinded
Location : Single center / Pakistan
Follow-up duration (days): 7
Inclusion criteria- All patients diagnosed with COVID-19 infection with positive reverse transcriptase RT-PCR test, who were willing to participate in this study;
- Patients having age of 18-75 years;
- Patients of both genders male and female;
- Patients who had mild symptoms of Corona virus disease and RT- PCR positive for SARSCov-2;
- Ability to take oral medication and were willing to adhere to the drug intake regimen
Exclusion criteriaKnown severe allergic reactions to Ivermectin;
- Pregnancy or breastfeeding;
- Severe symptoms likely attributed to Cytokine Release Storm;
- Malignant diseases ; Chronic kidney disease;
- Cirrhosis liver with Child class B or C
Interventions
Treatment
Ivermectin
12mg PO followed by 12 mg after 12 hours and 12mg after 24 hours
Control
Standard care
Definition of Standard care: symptomatic treatment
Participants
Randomized
50 participants (n1=25 / n2= 25)
Characteristics of participants
N=50
Mean age : 41.8
31 males
Severity : Mild: n=0 / Moderate: n=0/ Severe: n=0 Critical: n=0
Primary outcome
In the register
1.Resolution of symptoms [ Time Frame: 7 days ]
Will look for resolution of Fever, Fatigue, myalgias, cough and we had an questionaire for that as well and followed up on their chest x rays for progression of the disease
Progression of the disease [ Time Frame: 14 days ]
did the disease progress from mild to moderate severity, like follow up chest x ray showed more infiltrates or their oxygen saturations in % dropped from their baseline and baseline symptoms persisted and got worse
In the report
Improvement of symptoms like Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue at day 7.
Documents
available

Protocol

Yes. In English

Statistical plan

Yes

Data-sharing stated

Yes
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
High
General comment In addition to all available versions of the published/pre-print article, the study registry and protocol were used in data extraction and risk of bias assessment. The target sample size specified in the registry was achieved.There is no change from the trial registration in the intervention. The outcome "Progression of the disease [ Time Frame: 14 days ]" was mentioned in the register but not reported.
This study was updated on February 9th, 2021 after contact with authors.